🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07819175
Starting soon Not applicable

Pulsed Field Ablation for the Treatment of Persistent Atrial Fibrillation: Pulmonary Vein Plus Superior Vena Cava Isolation Versus Pulmonary Vein Isolation Alone-A Prospective, Multicenter, Randomized Controlled Study

NCT07819175 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Not applicable
Started
2026-10-08
Last updated
2026-09-14

Condition(s) studied

Persistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

Pulsed Field Ablation - pulmonary vein isolationPulsed Field Ablation - Pulmonary Vein Isolation + Superior Vena Cava Isolation

Pulsed Field Ablation - pulmonary vein isolation: Pulsed Field Ablation (PFA) using a commercially available pulsed field ablation catheter to perform pulmonary vein isolation (PVI). Ablation is performed sequentially at each pulmonary vein and the pulmonary vein antrum, with the procedural endpoint of durable bidirectional electrical isolation.

Pulsed Field Ablation - Pulmonary Vein Isolation + Superior Vena Cava Isolation: Pulsed Field Ablation (PFA) using a commercially available pulsed field ablation catheter to perform pulmonary vein isolation (PVI) followed by electrophysiological assessment for superior vena cava (SVC) triggers and additional superior vena cava isolation (SVCI) at the SVC-right atrium junction.

Study summary

his study is for people aged 18 to 75 who have persistent atrial fibrillation (AFib) that has lasted less than one year and who are having their first catheter ablation procedure.

Atrial fibrillation is a common heart rhythm problem. A standard treatment is a catheter procedure called pulmonary vein isolation (PVI), which uses energy to disconnect the pulmonary veins from the rest of the heart. However, in persistent AFib, the heart rhythm often returns after PVI alone.

Some people also have abnormal electrical signals coming from a large vein above the right atrium called the superior vena cava (SVC). This study tests whether adding SVC isolation (SVCI) to the standard PVI procedure works better than PVI alone.

The study will use pulsed field ablation (PFA), a newer non-heating technology that targets heart muscle cells and may cause less damage to nearby structures such as the food pipe and nerves.

About 340 participants will be enrolled from around 10 hospitals in China. Using a computer process, half will be assigned to PVI alone and half to PVI plus SVC isolation. Neither the doctor nor the participant will be blinded to the group assignment because the difference between the two procedures is visible.

All participants will be followed for 12 months after the procedure. The main question is: after a 3-month healing period, how many people stay free from AFib and other atrial rhythm problems for the remaining 9 months without needing more ablation or new rhythm medicines? The study also looks at safety, quality of life, hospital stays, and whether the heart rhythm returns.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Persistent atrial fibrillation (AFib) duration \< 1 year; 2. Age 18-75 years; 3. Willing to participate in this study, capable of understanding, and has signed the informed consent form; able to complete postoperative follow-up according to the protocol. Exclusion Criteria: 1. Significant cardiac dysfunction or structural abnormality: LVEF \< 50% or left atrial anteroposterior diameter \> 46 mm; 2. Previous left atrial ablation or cardiac surgery (including left atrial appendage closure); 3. Presence of permanent pacemaker, CRT, implantable cardiac monitor, or any type of ICD; 4. Previous pulmonary vein stent, pulmonary vein stenosis, or superior vena cava stenosis; 5. Previous unilateral phrenic nerve palsy; 6. Any prosthetic heart valve or moderate-to-severe (grade 3-4) valvular regurgitation/stenosis; 7. Any cardiac surgery, myocardial infarction, PCI/PTCA, or coronary stent implantation within 3 months prior to signing informed consent; 8. Unstable angina, NYHA class III/IV heart failure, primary pulmonary hypertension, rheumatic heart disease, or hypertrophic cardiomyopathy; 9. Thrombocytosis/thrombocytopenia, any disease contraindicating long-term anticoagulation, active systemic infection; 10. Atrial fibrillation due to reversible causes (e.g., hyperthyroidism); 11. Stroke or TIA within 6 months prior to signing informed consent; 12. Pregnant or lactating women; 13. Life expectancy \< 1 year; 14. Currently participating in or expected to participate in another drug/device/biologic clinical trial during the study period; 15. Intracardiac thrombus, drug or alcohol addiction, unwillingness or inability to complete follow-up; 16. Severe renal insufficiency (eGFR \< 30); 17. Previous catheter ablation for atrial fibrillation; 18. Primary severe sick sinus syndrome.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hostpial Shanghai Jiaotong University School of Medicine Shanghai Shanghai Municipality

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07819175 on ClinicalTrials.gov ↗ ← All trials in China